AIM
CPRX

Aigen Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Aigen Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,517
Closed -$732K – 728
2023
Q4 		$732K Buy
43,517
+25,737
+145% +$352K 0.13% 231
2023
Q3 		$208K Sell
17,780
-3,105
-15% -$41.5K 0.04% 658
2023
Q2 		$281K Buy
+20,885
New +$301K 0.04% 513
2022
Q4 		– Sell
-57,986
Closed -$744K – 571
2022
Q3 		$744K Buy
+57,986
New +$687K 0.11% 240
2020
Q1 		– Sell
-15,273
Closed -$57K – 1308
2019
Q4 		$57K Buy
+15,273
New +$71.4K 0.01% 789

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aigen Investment Management's CPRX Position: Q1 2024 in Review

Aigen Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 43,517 shares — an estimated $732K sold.

Aigen Investment Management first reported a position in CPRX in Q4 2019 and held it in 5 quarters. The position peaked at $744K in Q3 2022. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Aigen Investment Management reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Aigen Investment Management sold 43,517 Catalyst Pharmaceutical shares in Q1 2024, an estimated $732K.
  • Aigen Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 5 quarters.
  • Aigen Investment Management's Catalyst Pharmaceutical position peaked at $744K in Q3 2022.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.